DAVENPORT & Co LLC Has $18.86 Million Stock Position in ALPS Medical Breakthroughs ETF $SBIO

DAVENPORT & Co LLC lowered its position in ALPS Medical Breakthroughs ETF (NYSEARCA:SBIOFree Report) by 29.2% in the third quarter, HoldingsChannel.com reports. The fund owned 485,412 shares of the company’s stock after selling 200,225 shares during the quarter. DAVENPORT & Co LLC owned about 0.20% of ALPS Medical Breakthroughs ETF worth $18,863,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of SBIO. Raymond James Financial Inc. acquired a new position in ALPS Medical Breakthroughs ETF during the 2nd quarter worth $82,000. Ally Invest Advisors Inc. acquired a new position in shares of ALPS Medical Breakthroughs ETF during the 2nd quarter worth about $200,000. Strategic Financial Services Inc. increased its stake in ALPS Medical Breakthroughs ETF by 97.8% in the second quarter. Strategic Financial Services Inc. now owns 38,032 shares of the company’s stock valued at $1,144,000 after purchasing an additional 18,807 shares in the last quarter. Moran Wealth Management LLC bought a new position in ALPS Medical Breakthroughs ETF during the second quarter worth about $300,000. Finally, Jones Financial Companies Lllp acquired a new position in shares of ALPS Medical Breakthroughs ETF in the 1st quarter valued at approximately $782,000.

ALPS Medical Breakthroughs ETF Stock Up 2.0%

Shares of NYSEARCA SBIO opened at $52.90 on Thursday. ALPS Medical Breakthroughs ETF has a 1-year low of $22.33 and a 1-year high of $52.90. The company has a fifty day moving average price of $47.17 and a 200 day moving average price of $38.88.

ALPS Medical Breakthroughs ETF Profile

(Free Report)

The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.

Featured Stories

Want to see what other hedge funds are holding SBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ALPS Medical Breakthroughs ETF (NYSEARCA:SBIOFree Report).

Institutional Ownership by Quarter for ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO)

Receive News & Ratings for ALPS Medical Breakthroughs ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALPS Medical Breakthroughs ETF and related companies with MarketBeat.com's FREE daily email newsletter.